PHIBRO ANIMAL HEALTH CORP (PAHC) Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Phibro Animal Health Corporation NASDAQ:PAHC Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $1.39B
Div Yield 1.40%
Prev close $32.96 Open $33.33 Now $34.18 VOL 40K $ Vol $1.36M RVOL 0.19x
Mkt Cap $1.39B
VOL 40K sh
$ Vol $1.36M
RVOL 0.19×
Div Yield 1.40%
Press Release ⚠ 3
Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance
Phibro reported Q1 net sales of $386.8 million, up 6% year-over-year, with net income of $29.5 million, up 11%, and adjusted diluted EPS of $0.79, up 8%.
Management said results exceeded expectations, led by Mineral Nutrition (+17%) and Performance Products (+16%), while core Animal Health grew 3% despite a $5.2 million decline in Brazil virginiamycin sales tied to regulatory delays.
The company maintained its FY27 guidance (net sales $1.55B-$1.60B, adjusted EBITDA $258M-$268M); any Brazil regulatory approval for virginiamycin would represent potential upside, as guidance assumes no additional sales there.
Free cash flow was $21.7 million on a trailing-twelve-month basis with a 2.9x gross leverage ratio; management flagged working capital and cash conversion improvement as a top priority.
• 4d ago AI analysis › Press Release
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health's board declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock.
The dividend is payable December 16, 2026, to stockholders of record at the close of business on November 25, 2026.
This is a routine continuation of the existing dividend policy with no change to the payout amount.
• 5d ago AI analysis › Press Release
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
Phibro Animal Health will announce first quarter financial results on November 4, 2026, after the market close.
Management will host a conference call and webcast on November 5, 2026, at 9:00 AM ET, with a replay available on the investor relations site.
This is a routine scheduling notice with no financial results or guidance included.
• 11d ago AI analysis › Press Release
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference
Phibro Animal Health Corporation (Nasdaq: PAHC) announced it will participate in the Morgan Stanley Annual Global Healthcare Conference in New York.
President & CEO Daniel Bendheim, COO Larry Miller, and CFO Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at the New York Marriott Marquis.
A live audio presentation will stream on Phibro's investor relations website, with a replay archived afterward.
This is a routine conference-scheduling notice containing no new financial disclosure; any incremental commentary would come out of the September 15 session itself.
• 1mo ago AI analysis › Press Release ● Major ⚠ 4
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Phibro Animal Health delivered fiscal 2026 net sales of $1.52 billion, up 17% year-over-year, while Adjusted EBITDA surged 39% to $255 million driven by the MFA acquisition and organic growth.
For fiscal 2027, the company guided for net sales of $1.55 billion to $1.60 billion and adjusted diluted EPS of $3.41 to $3.59, reflecting an anticipated regulatory headwind in Brazil regarding virginiamycin sales.
Management announced the strategic closure of the Chicago Heights manufacturing facility in summer 2027 to consolidate its footprint and confirmed the formal conclusion of its Phibro Forward transformation program.
• 2mo ago AI analysis › Press Release
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
Phibro Animal Health plans to announce its fourth quarter and fiscal year 2026 financial results on August 26, 2026, after the market closes.
Management will host a conference call and webcast on August 27, 2026, at 9:00 AM ET to discuss the results.
• 2mo ago AI analysis › Press Release
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation's Board of Directors declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock.
The dividend is payable on September 23, 2026, to stockholders of record at the close of business on September 2, 2026.
• 3mo ago AI analysis › Press Release
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
Phibro Animal Health will participate in the Stifel Jaws & Paws Conference on May 27, 2026.
Executive Vice President Daniel Bendheim, COO Larry Miller, and CFO Glenn David are scheduled to address analysts and investors at 9:45 AM ET in New York.
The session will be streamed live on the company’s investor relations website with a replay archived afterward.
• 5mo ago AI analysis › Press Release
Phibro Animal Health Corporation to Participate in Bank of America Securities Health Care Conference
Phibro Animal Health will participate in the Bank of America Securities Health Care Conference on May 13, 2026, with key executives addressing analysts and investors.
The live presentation will be available on the company's Investor Relations website, with a replay archived afterward.
This is a routine investor relations engagement with no new financial or operational disclosures.
• 6mo ago AI analysis › Press Release ● Major ⚠ 1
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Phibro Animal Health reported Q3 net sales of $383.5 million, up 10% year-over-year, driven by a 13% increase in its Animal Health segment.
Adjusted EBITDA rose 11% to $60.8 million, while net income increased 15% to $24.0 million.
The company raised its full-year fiscal 2026 guidance, now projecting net sales of $1.46 billion to $1.50 billion and Adjusted EBITDA of $247 million to $255 million.
• 6mo ago AI analysis › Press Release
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock.
The dividend is payable on June 24, 2026, to stockholders of record at the close of business on June 3, 2026.
This is a routine declaration maintaining the company's existing capital return policy.
• 6mo ago AI analysis › Press Release
Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership
Phibro Animal Health launched its Sustainable Solutions Platform and introduced the Verratain brand of low-carbon microalgae feed ingredients, produced in partnership with VAXA Technologies.
The initial product line, featuring Verratain Spirulina and Verratain Omega Oil, aims to help producers reduce Scope 3 emissions and meet sustainability goals.
Management anticipates initial sales to commence in the coming months, targeting a market with an estimated $80–300 billion annual decarbonization value signal.
• 6mo ago AI analysis › Press Release
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
Phibro Animal Health Corporation plans to announce its third quarter financial results on Wednesday, May 6, 2026, after the market closes.
Management is scheduled to host a conference call and webcast to discuss the results on Thursday, May 7, 2026, at 9:00 AM Eastern Time.
A replay of the webcast will be available approximately two hours after the conclusion of the live event.
• 6mo ago AI analysis › Press Release ⚠ 2
Phibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials
Brazil's Ministry of Agriculture published an ordinance banning performance-enhancing feed additives containing antimicrobials like virginiamycin and bacitracin, aligning the country with global regulatory standards.
The prohibition includes a 180-day transition period during which Phibro expects to secure therapeutic-use registrations for virginiamycin, while bacitracin already holds therapeutic claims.
Management anticipates limited impact on fiscal 2026 results and is launching PhibroVet®, a digital platform to manage the veterinary prescriptions required under the new framework.
• 6mo ago AI analysis › 
